163 related articles for article (PubMed ID: 32635985)
1. Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes.
Almeida BO; Machado-Neto JA
BMB Rep; 2020 Aug; 53(8):413-418. PubMed ID: 32635985
[TBL] [Abstract][Full Text] [Related]
2. ANKHD1 promotes proliferation and invasion of non‑small‑cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway.
Liu XF; Han Q; Rong XZ; Yang M; Han YC; Yu JH; Lin XY
Int J Oncol; 2020 May; 56(5):1175-1185. PubMed ID: 32319569
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in Cancer.
Mullenger JL; Zeidler MP; Fragiadaki M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629022
[TBL] [Abstract][Full Text] [Related]
4. Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs.
Fragiadaki M; Zeidler MP
J Biol Chem; 2018 Jun; 293(25):9570-9579. PubMed ID: 29695508
[TBL] [Abstract][Full Text] [Related]
5. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.
Machado-Neto JA; Lazarini M; Favaro P; Franchi GC; Nowill AE; Saad ST; Traina F
Exp Cell Res; 2014 Jun; 324(2):137-45. PubMed ID: 24726915
[TBL] [Abstract][Full Text] [Related]
6. ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells.
de Almeida BO; de Almeida LC; Costa-Lotufo LV; Machado-Neto JA
Cell Biol Int; 2022 Sep; 46(9):1433-1446. PubMed ID: 35842770
[TBL] [Abstract][Full Text] [Related]
7. ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells.
Machado-Neto JA; Lazarini M; Favaro P; de Melo Campos P; Scopim-Ribeiro R; Franchi Junior GC; Nowill AE; Lima PR; Costa FF; Benichou S; Olalla Saad ST; Traina F
Biochim Biophys Acta; 2015 Mar; 1853(3):583-93. PubMed ID: 25523139
[TBL] [Abstract][Full Text] [Related]
8. CPEB3 functions as a tumor suppressor in colorectal cancer via JAK/STAT signaling.
Fang Y; Zhong Q; Wang Y; Gu C; Liu S; Li A; Yan Q
Aging (Albany NY); 2020 Nov; 12(21):21404-21422. PubMed ID: 33146632
[TBL] [Abstract][Full Text] [Related]
9. ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth.
Dhyani A; Machado-Neto JA; Favaro P; Saad ST
Eur J Cancer; 2015 Jan; 51(2):252-9. PubMed ID: 25483783
[TBL] [Abstract][Full Text] [Related]
10. ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells.
Dhyani A; Favaro P; Olalla Saad ST
Blood Cells Mol Dis; 2020 Sep; 84():102460. PubMed ID: 32562952
[TBL] [Abstract][Full Text] [Related]
11. Molecular and functional characterization of a novel splice variant of ANKHD1 that lacks the KH domain and its role in cell survival and apoptosis.
Miles MC; Janket ML; Wheeler ED; Chattopadhyay A; Majumder B; Dericco J; Schafer EA; Ayyavoo V
FEBS J; 2005 Aug; 272(16):4091-102. PubMed ID: 16098192
[TBL] [Abstract][Full Text] [Related]
12. ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT.
Yao P; Li Y; Shen W; Xu X; Zhu W; Yang X; Cao J; Xing C
Am J Cancer Res; 2018; 8(11):2311-2324. PubMed ID: 30555746
[TBL] [Abstract][Full Text] [Related]
13. ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells.
Dhyani A; Duarte AS; Machado-Neto JA; Favaro P; Ortega MM; Olalla Saad ST
FEBS Lett; 2012 Dec; 586(24):4311-8. PubMed ID: 23142581
[TBL] [Abstract][Full Text] [Related]
14. Stathmin 1 promotes the progression of liver cancer through interacting with YAP1.
Liu YP; Pan LL; Kong CC
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7335-7344. PubMed ID: 32706072
[TBL] [Abstract][Full Text] [Related]
15. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
16. ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells.
Traina F; Favaro PM; Medina Sde S; Duarte Ada S; Winnischofer SM; Costa FF; Saad ST
Biochim Biophys Acta; 2006 Sep; 1762(9):828-34. PubMed ID: 16956752
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.
Hubackova S; Novakova Z; Krejcikova K; Kosar M; Dobrovolna J; Duskova P; Hanzlikova H; Vancurova M; Barath P; Bartek J; Hodny Z
Cell Cycle; 2010 Aug; 9(15):3085-99. PubMed ID: 20699642
[TBL] [Abstract][Full Text] [Related]
18. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
19. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
20. KMT Set7/9 is a new regulator of Sam68 STAR-protein.
Vasileva E; Shuvalov O; Petukhov A; Fedorova O; Daks A; Nader R; Barlev N
Biochem Biophys Res Commun; 2020 May; 525(4):1018-1024. PubMed ID: 32178870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
